Your browser doesn't support javascript.
loading
Decade-long leukaemia remissions with persistence of CD4+ CAR T cells.
Melenhorst, J Joseph; Chen, Gregory M; Wang, Meng; Porter, David L; Chen, Changya; Collins, McKensie A; Gao, Peng; Bandyopadhyay, Shovik; Sun, Hongxing; Zhao, Ziran; Lundh, Stefan; Pruteanu-Malinici, Iulian; Nobles, Christopher L; Maji, Sayantan; Frey, Noelle V; Gill, Saar I; Loren, Alison W; Tian, Lifeng; Kulikovskaya, Irina; Gupta, Minnal; Ambrose, David E; Davis, Megan M; Fraietta, Joseph A; Brogdon, Jennifer L; Young, Regina M; Chew, Anne; Levine, Bruce L; Siegel, Donald L; Alanio, Cécile; Wherry, E John; Bushman, Frederic D; Lacey, Simon F; Tan, Kai; June, Carl H.
Afiliación
  • Melenhorst JJ; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. mej@pennmedicine.upenn.edu.
  • Chen GM; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. mej@pennmedicine.upenn.edu.
  • Wang M; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. mej@pennmedicine.upenn.edu.
  • Porter DL; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. mej@pennmedicine.upenn.edu.
  • Chen C; Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia, USA. mej@pennmedicine.upenn.edu.
  • Collins MA; Graduate Group in Genomics and Computational Biology, University of Pennsylvania, Philadelphia, PA, USA.
  • Gao P; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Bandyopadhyay S; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Sun H; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Zhao Z; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Lundh S; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Pruteanu-Malinici I; Center for Childhood Cancer Research, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Nobles CL; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
  • Maji S; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Frey NV; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Gill SI; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Loren AW; Graduate Group in Cell & Molecular Biology, University of Pennsylvania, Philadelphia, PA, USA.
  • Tian L; Center for Childhood Cancer Research, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Kulikovskaya I; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
  • Gupta M; Graduate Group in Cell & Molecular Biology, University of Pennsylvania, Philadelphia, PA, USA.
  • Ambrose DE; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Davis MM; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Fraietta JA; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Brogdon JL; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Young RM; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Chew A; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Levine BL; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Siegel DL; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Alanio C; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Wherry EJ; Novartis Institute for Biomedical Research, Cambridge, MA, USA.
  • Bushman FD; Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Lacey SF; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Tan K; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • June CH; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Nature ; 602(7897): 503-509, 2022 02.
Article en En | MEDLINE | ID: mdl-35110735
ABSTRACT
The adoptive transfer of T lymphocytes reprogrammed to target tumour cells has demonstrated potential for treatment of various cancers1-7. However, little is known about the long-term potential and clonal stability of the infused cells. Here we studied long-lasting CD19-redirected chimeric antigen receptor (CAR) T cells in two patients with chronic lymphocytic leukaemia1-4 who achieved a complete remission in 2010. CAR T cells remained detectable more than ten years after infusion, with sustained remission in both patients. Notably, a highly activated CD4+ population emerged in both patients, dominating the CAR T cell population at the later time points. This transition was reflected in the stabilization of the clonal make-up of CAR T cells with a repertoire dominated by a small number of clones. Single-cell profiling demonstrated that these long-persisting CD4+ CAR T cells exhibited cytotoxic characteristics along with ongoing functional activation and proliferation. In addition, longitudinal profiling revealed a population of gamma delta CAR T cells that prominently expanded in one patient concomitant with CD8+ CAR T cells during the initial response phase. Our identification and characterization of these unexpected CAR T cell populations provide novel insight into the CAR T cell characteristics associated with anti-cancer response and long-term remission in leukaemia.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Linfocitos T CD4-Positivos / Leucemia / Inmunoterapia Adoptiva / Receptores Quiméricos de Antígenos Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Nature Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Linfocitos T CD4-Positivos / Leucemia / Inmunoterapia Adoptiva / Receptores Quiméricos de Antígenos Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Nature Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos